User login
Single-agent ibrutinib has had sustained efficacy and a rate of complete response that has increased over time, according to a 5-year follow-up report including 132 patients with chronic lymphocytic leukemia (CLL).
Efficacy has been maintained in both treatment-naive and relapsed/refractory CLL, despite the presence of high-risk genomic features in many patients, investigators reported in Blood.
Treatment has been well tolerated, and the occurrence of severe adverse events has diminished over time, according to Susan M. O’Brien, MD, of the Chao Family Comprehensive Cancer Center, University of California, Irvine, and her colleagues.
“The safety profile of ibrutinib over time remains acceptable and manageable, allowing almost one-half of the patients (48%) to be treated for more than 4 years and thus maximize response,” the investigators wrote.
The report was based on 5-year follow-up of patients with CLL who had been enrolled in a phase 1b/2 study (PCYC-1102) and an extension study (PCYC-1103). A total of 132 patients were evaluated, including 101 with relapsed/refractory disease and 31 who were treatment naive.
The overall response rate remained high, at 89% in this 5-year follow-up. Complete response rates increased over time, reaching 29% in treatment-naive patients and 10% in relapsed/refractory patients. In a previous report on 3-year follow-up for these patients, investigators reported complete response rates of 23% in the previously untreated group and 7% in the relapsed/refractory group. The new findings demonstrate “deepening of responses” with continued ibrutinib therapy, Dr. O’Brien and her coauthors wrote.
The 5-year rate of progression-free survival was 44% for relapsed/refractory patients and 92% for treatment-naive patients in this study. Median progression-free survival was 51 months for the relapsed/refractory cohort. “[Progression-free survival] with single-agent ibrutinib in [treatment-naive] patients appears particularly favorable, because the median has not been reached,” investigators wrote.
Adverse events that limited treatment were more frequent during the first year of treatment than in subsequent years, data show, while new onset of neutropenia and thrombocytopenia decreased over time.
The overall response rate was high even in patients with high-risk genetic features. Rates of overall response ranged from 79% to 97%, depending on genomic subgroup. That held true for relapsed/refractory CLL patients with del(17p), a significant negative prognostic factor for survival. In that group, the overall response rate was 79% and the duration of response was 31 months, representing “promising single-agent efficacy” in that group, investigators said.
Pharmacyclics, an AbbVie Company, provided funding for the study and writing support. The study was also supported by grants from the National Institutes of Health and a private foundation. Dr. O’Brien reported ties to AbbVie, Janssen, and Pharmacyclics. Other investigators reported financial relationships with various pharmaceutical companies.
SOURCE: O’Brien S et al. Blood. 2018;131(17):1910-9.
This report on the 5-year experience with single-agent ibrutinib in chronic lymphocytic leukemia (CLL) is a step forward in knowledge of the drug’s natural history, according to Jennifer R. Brown, MD, PhD.
“Ibrutinib data are starting to mature, but much opportunity for growth remains,” Dr. Brown said in an editorial.
One notable update in the report is that a median, progression-free survival has been reached in patients with relapsed/refractory CLL. The reported 51-month median progression-free survival is “strikingly good” in this cohort of patients with high-risk disease, and compares favorably to older regimens in similar patient populations, she said.
Regarding previously untreated CLL patients, it is notable that 45% of this cohort discontinued treatment, many apparently after year 4, Dr. Brown said. The finding that median duration on therapy was just about 5.5 years in the cohort could be “potentially quite useful” in counseling patients, if confirmed in a larger cohort, she added.
Given the discontinuation data, one unanswered question is the durability of remission after stopping ibrutinib in a “deep but probably not complete remission” versus continuing therapy.
“Further follow-up of patients who discontinue without disease progression, as well as systematic investigation of time-limited therapy, including novel likely combination approaches, is clearly warranted,” Dr. Brown said in her editorial.
Dr. Jennifer R. Brown is with the Dana-Farber Cancer Institute in Boston. These comments are adapted an accompanying editorial ( Blood. 2018;131:1880-2 ). Dr. Brown reported ties to Janssen, Pharmacyclics, AstraZeneca, Sun, Redx, Sunesis, Loxo, Gilead, TG Therapeutics, Verastem, and AbbVie.
This report on the 5-year experience with single-agent ibrutinib in chronic lymphocytic leukemia (CLL) is a step forward in knowledge of the drug’s natural history, according to Jennifer R. Brown, MD, PhD.
“Ibrutinib data are starting to mature, but much opportunity for growth remains,” Dr. Brown said in an editorial.
One notable update in the report is that a median, progression-free survival has been reached in patients with relapsed/refractory CLL. The reported 51-month median progression-free survival is “strikingly good” in this cohort of patients with high-risk disease, and compares favorably to older regimens in similar patient populations, she said.
Regarding previously untreated CLL patients, it is notable that 45% of this cohort discontinued treatment, many apparently after year 4, Dr. Brown said. The finding that median duration on therapy was just about 5.5 years in the cohort could be “potentially quite useful” in counseling patients, if confirmed in a larger cohort, she added.
Given the discontinuation data, one unanswered question is the durability of remission after stopping ibrutinib in a “deep but probably not complete remission” versus continuing therapy.
“Further follow-up of patients who discontinue without disease progression, as well as systematic investigation of time-limited therapy, including novel likely combination approaches, is clearly warranted,” Dr. Brown said in her editorial.
Dr. Jennifer R. Brown is with the Dana-Farber Cancer Institute in Boston. These comments are adapted an accompanying editorial ( Blood. 2018;131:1880-2 ). Dr. Brown reported ties to Janssen, Pharmacyclics, AstraZeneca, Sun, Redx, Sunesis, Loxo, Gilead, TG Therapeutics, Verastem, and AbbVie.
This report on the 5-year experience with single-agent ibrutinib in chronic lymphocytic leukemia (CLL) is a step forward in knowledge of the drug’s natural history, according to Jennifer R. Brown, MD, PhD.
“Ibrutinib data are starting to mature, but much opportunity for growth remains,” Dr. Brown said in an editorial.
One notable update in the report is that a median, progression-free survival has been reached in patients with relapsed/refractory CLL. The reported 51-month median progression-free survival is “strikingly good” in this cohort of patients with high-risk disease, and compares favorably to older regimens in similar patient populations, she said.
Regarding previously untreated CLL patients, it is notable that 45% of this cohort discontinued treatment, many apparently after year 4, Dr. Brown said. The finding that median duration on therapy was just about 5.5 years in the cohort could be “potentially quite useful” in counseling patients, if confirmed in a larger cohort, she added.
Given the discontinuation data, one unanswered question is the durability of remission after stopping ibrutinib in a “deep but probably not complete remission” versus continuing therapy.
“Further follow-up of patients who discontinue without disease progression, as well as systematic investigation of time-limited therapy, including novel likely combination approaches, is clearly warranted,” Dr. Brown said in her editorial.
Dr. Jennifer R. Brown is with the Dana-Farber Cancer Institute in Boston. These comments are adapted an accompanying editorial ( Blood. 2018;131:1880-2 ). Dr. Brown reported ties to Janssen, Pharmacyclics, AstraZeneca, Sun, Redx, Sunesis, Loxo, Gilead, TG Therapeutics, Verastem, and AbbVie.
Single-agent ibrutinib has had sustained efficacy and a rate of complete response that has increased over time, according to a 5-year follow-up report including 132 patients with chronic lymphocytic leukemia (CLL).
Efficacy has been maintained in both treatment-naive and relapsed/refractory CLL, despite the presence of high-risk genomic features in many patients, investigators reported in Blood.
Treatment has been well tolerated, and the occurrence of severe adverse events has diminished over time, according to Susan M. O’Brien, MD, of the Chao Family Comprehensive Cancer Center, University of California, Irvine, and her colleagues.
“The safety profile of ibrutinib over time remains acceptable and manageable, allowing almost one-half of the patients (48%) to be treated for more than 4 years and thus maximize response,” the investigators wrote.
The report was based on 5-year follow-up of patients with CLL who had been enrolled in a phase 1b/2 study (PCYC-1102) and an extension study (PCYC-1103). A total of 132 patients were evaluated, including 101 with relapsed/refractory disease and 31 who were treatment naive.
The overall response rate remained high, at 89% in this 5-year follow-up. Complete response rates increased over time, reaching 29% in treatment-naive patients and 10% in relapsed/refractory patients. In a previous report on 3-year follow-up for these patients, investigators reported complete response rates of 23% in the previously untreated group and 7% in the relapsed/refractory group. The new findings demonstrate “deepening of responses” with continued ibrutinib therapy, Dr. O’Brien and her coauthors wrote.
The 5-year rate of progression-free survival was 44% for relapsed/refractory patients and 92% for treatment-naive patients in this study. Median progression-free survival was 51 months for the relapsed/refractory cohort. “[Progression-free survival] with single-agent ibrutinib in [treatment-naive] patients appears particularly favorable, because the median has not been reached,” investigators wrote.
Adverse events that limited treatment were more frequent during the first year of treatment than in subsequent years, data show, while new onset of neutropenia and thrombocytopenia decreased over time.
The overall response rate was high even in patients with high-risk genetic features. Rates of overall response ranged from 79% to 97%, depending on genomic subgroup. That held true for relapsed/refractory CLL patients with del(17p), a significant negative prognostic factor for survival. In that group, the overall response rate was 79% and the duration of response was 31 months, representing “promising single-agent efficacy” in that group, investigators said.
Pharmacyclics, an AbbVie Company, provided funding for the study and writing support. The study was also supported by grants from the National Institutes of Health and a private foundation. Dr. O’Brien reported ties to AbbVie, Janssen, and Pharmacyclics. Other investigators reported financial relationships with various pharmaceutical companies.
SOURCE: O’Brien S et al. Blood. 2018;131(17):1910-9.
Single-agent ibrutinib has had sustained efficacy and a rate of complete response that has increased over time, according to a 5-year follow-up report including 132 patients with chronic lymphocytic leukemia (CLL).
Efficacy has been maintained in both treatment-naive and relapsed/refractory CLL, despite the presence of high-risk genomic features in many patients, investigators reported in Blood.
Treatment has been well tolerated, and the occurrence of severe adverse events has diminished over time, according to Susan M. O’Brien, MD, of the Chao Family Comprehensive Cancer Center, University of California, Irvine, and her colleagues.
“The safety profile of ibrutinib over time remains acceptable and manageable, allowing almost one-half of the patients (48%) to be treated for more than 4 years and thus maximize response,” the investigators wrote.
The report was based on 5-year follow-up of patients with CLL who had been enrolled in a phase 1b/2 study (PCYC-1102) and an extension study (PCYC-1103). A total of 132 patients were evaluated, including 101 with relapsed/refractory disease and 31 who were treatment naive.
The overall response rate remained high, at 89% in this 5-year follow-up. Complete response rates increased over time, reaching 29% in treatment-naive patients and 10% in relapsed/refractory patients. In a previous report on 3-year follow-up for these patients, investigators reported complete response rates of 23% in the previously untreated group and 7% in the relapsed/refractory group. The new findings demonstrate “deepening of responses” with continued ibrutinib therapy, Dr. O’Brien and her coauthors wrote.
The 5-year rate of progression-free survival was 44% for relapsed/refractory patients and 92% for treatment-naive patients in this study. Median progression-free survival was 51 months for the relapsed/refractory cohort. “[Progression-free survival] with single-agent ibrutinib in [treatment-naive] patients appears particularly favorable, because the median has not been reached,” investigators wrote.
Adverse events that limited treatment were more frequent during the first year of treatment than in subsequent years, data show, while new onset of neutropenia and thrombocytopenia decreased over time.
The overall response rate was high even in patients with high-risk genetic features. Rates of overall response ranged from 79% to 97%, depending on genomic subgroup. That held true for relapsed/refractory CLL patients with del(17p), a significant negative prognostic factor for survival. In that group, the overall response rate was 79% and the duration of response was 31 months, representing “promising single-agent efficacy” in that group, investigators said.
Pharmacyclics, an AbbVie Company, provided funding for the study and writing support. The study was also supported by grants from the National Institutes of Health and a private foundation. Dr. O’Brien reported ties to AbbVie, Janssen, and Pharmacyclics. Other investigators reported financial relationships with various pharmaceutical companies.
SOURCE: O’Brien S et al. Blood. 2018;131(17):1910-9.
FROM BLOOD
Key clinical point:
Major finding: The 5-year rate of progression-free survival was 44% for relapsed/refractory patients and 92% for treatment-naive patients.
Study details: Report on 5-year follow-up of 132 patients with CLL enrolled in a phase 1b/2 study (PCYC-1102) and an extension study (PCYC-1103).
Disclosures: Pharmacyclics, an AbbVie Company, provided funding for the study and writing support. The study was also supported by grants from the National Institutes of Health and a private foundation. The authors reported ties to Pharmacyclics and other companies.
Source: O’Brien S et al. Blood. 2018;131(17):1910-9.